Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02185053 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
A Phase 2 study, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02185053 is a Phase 2 study that has completed, run by Chase Pharmaceuticals Corporation, an affiliate of Allergan. The registered enrollment target is 41 participants.
The verdict
NCT02185053, a Phase 2 study, has completed, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
Interventions
- DRUG CPC-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-07-31 |
| Est. Completion | 2016-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02185053
The ClinicalTrials.gov registry entry for NCT02185053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPC-201 is the first listed.
NCT02185053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02185053 about?
NCT02185053 is a clinical study titled "A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia". This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
What is the current status of trial NCT02185053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2014-07-31. Estimated completion is 2016-07-31.
What interventions are being tested in trial NCT02185053?
The interventions under investigation include: CPC-201 (DRUG).
Who is sponsoring clinical trial NCT02185053?
This trial is sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.